Celldex (CLDX) Reports Q2 Loss of $0.33
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Celldex (CLDX) Reports Q2 Loss of $0.33
August 11, 2015 10:10 AM EDT
Cantor Fitzgerald maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $38.00), following its decision to delay BLA filing for Rintega. Analyst Mara Goldstein said that filing for Rintega is not likely until the completion of ACT IV. ACT IV is expected... More
August 11, 2015 8:11 AM EDT
Roth Capital trims its price target on Celldex Therapeutics (Nasdaq: CLDX) from $43 down to $39 following Q2 results issued after markets closed Monday.
Analyst Joseph Pantginis commented, The key point to the 2Q15 results call, which we believe will drive perception for the... More
August 11, 2015 7:07 AM EDT
Brean Capital maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $35.00), following company talks with the FDA. CLDX has received enough feedback to conclude that it will not file Rintega for Accelerated Approval in recurrent GBM.
Analyst... More
August 11, 2015 6:58 AM EDT
Cowen maintained an Outperform rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $28.00 (from $34.00), following 2Q earnings and clinical update. CLDX has decided not to file for acceleration of Rintega. Analyst Boris Peaker is disappointed by the rindo filing... More
